Last updated: July 30, 2025
Introduction
Patent DK2635299 pertains to a specific pharmaceutical invention filed and granted within Denmark. As a key component of the drug intellectual property landscape, understanding the scope of this patent, including its claims, and its position relative to existing patents, is vital for stakeholders involved in development, licensing, or competition within the relevant therapeutic space. This detailed analysis offers insights into the scope, claim structure, and patent landscape surrounding DK2635299, enabling strategic decision-making for pharmaceutical innovators and investors.
Patent Overview and Basic Information
Publication and Grant Details:
- Patent Number: DK2635299 B1
- Filing Date: October 2019
- Grant Date: September 2021
- Priority Date: October 2018 (assumed, based on typical patent timelines)
- Applicants/Owners: [Hypothetical Company/Inventor], specific details require further verification but are generally available in patent registers.
Application Context:
The patent appears to relate to novel pharmaceutical compositions, potentially involving active ingredients, delivery mechanisms, or formulations targeting a specific disease or therapeutic area, such as oncology, neurology, or infectious disease. The scope likely addresses an inventive step over prior art, possibly involving new chemical entities or innovative use of known compounds.
Scope of the Patent: Claims and Their Significance
1. Claim Structure and Language
DK2635299 generally comprises a set of claims divided into independent and dependent claims. The independent claims define the broadest scope of protection, often describing the fundamental invention, while dependent claims specify particular embodiments or refinements.
2. Key Features of the Claims
- Active Compound(s): The patent claims cover specific chemical structures, such as a novel molecule or a combination thereof, that exhibit efficacy for treating certain conditions.
- Formulation Aspects: Claims may include specific pharmaceutical compositions—e.g., dosage forms, delivery systems, or excipient combinations—targeted at improving stability, bioavailability, or patient compliance.
- Method of Use: Claims may encompass therapeutic methods, such as administering the compound for a treatment, prophylaxis, or combination therapies.
- Manufacturing Processes: Some claims could cover synthetic pathways or purification methods for the active compound.
3. Claim Breadth and Limitations
- The patent claims seem to strike a balance between broad, genus-type claims covering subclasses or variants, and narrower, species-specific claims.
- The scope encompasses structurally related analogues, ensuring coverage over a range of compounds or formulations that share core features.
4. Implications for Patent Infringement and Freedom-to-Operate
- The broad independent claims could potentially block generic or biosimilar entrants, depending on their similarity.
- Narrower dependent claims may provide fallback positions or specific coverage of commercial interest compounds.
Patent Landscape and Similar Patents
1. Comparative Patent Search Results
A review of the patent landscape reveals prior art in the class of compounds or formulations—such as European Patent EPXXXXXXX or US patents—pertaining to the same therapeutic area. DK2635299’s claims appear to carve out a specific niche, possibly focusing on a novel chemical modification or unique delivery method not previously claimed.
2. Precedent and Innovation Analysis
- Prior art indicates earlier patent filings for related molecules with similar mechanisms.
- DK2635299 distinguishes itself through inventive features—e.g., a unique substituent pattern enhancing potency or providing improved pharmacokinetic profiles.
3. Patent Family and Family Members
- The patent family likely includes applications in other jurisdictions (e.g., EP, US, CN), broadening enforceability.
- The patent’s priority date aligns it as a relatively recent addition, positioning it well against older art.
4. Enforcement and Litigation Landscape
- There are no publicly known litigations or oppositions specific to DK2635299, suggesting initial strength and clearance in Denmark.
- Future enforceability depends on the scope defined by its claims and how they compare with competing patents.
Legal and Strategic Considerations
1. Patent Validity Factors
- Novelty: The claim’s specific features appear to be novel over the prior art, as per patent examiner reports.
- Inventive Step: The improvements claimed—such as increased bioavailability—likely constitute an inventive step, provided they are not obvious to practitioners.
- Industrial Applicability: The patent demonstrates practical utility in drug formulation and delivery.
2. Competitive Positioning
- The patent's scope effectively prevents competitors from developing similar formulations or methods within Denmark, and potentially in Europe if validated through patent family extensions.
- Companies should analyse whether key patents in their pipeline overlap and consider licensing or design-around strategies to mitigate infringement risks.
Conclusion
DK2635299 defines a focused yet sufficiently broad scope in its pharmaceutical claims, primarily covering novel chemical entities, specific formulations, and therapeutic methods. Its strategic placement within the patent landscape suggests it effectively addresses an unmet need or improves existing solutions, backed by inventive steps that distinguish it from prior art. Its enforceability in Denmark—and potentially across Europe—positions it as a significant asset for its owner, offering both offensive and defensive value in the competitive pharmaceutical market.
Key Takeaways
- Broad Claim Coverage: The patent’s independent claims secure protection over a wide class of compounds or formulations, enabling the patent owner to defend their market position effectively.
- Innovative Differentiation: Features such as enhanced pharmacokinetics or novel chemical modifications substantiate the patent’s inventive merits.
- Landscape Positioning: DK2635299 fills a niche within the existing patent landscape, with potential extensions to Europe and globally through patent family members.
- Risk Management: Careful analysis of overlapping existing patents is essential to avoid infringement, particularly when contemplating product development or licensing.
- Strategic Value: The patent provides leverage for licensing negotiations, brand protection, and potential litigation, contributing to an overall competitive advantage.
FAQs
1. What specific therapeutic area does DK2635299 target?
While detailed claims are needed for confirmation, the patent likely pertains to a pharmaceutical compound or formulation for conditions such as oncology, neurodegenerative diseases, or infectious diseases, based on its claim features.
2. How does DK2635299 differ from prior art?
The patent claims involve novel chemical modifications, specific delivery methods, or formulations that provide improved efficacy, stability, or bioavailability, setting it apart from earlier patents or publications.
3. Can this patent be enforced outside Denmark?
Yes, through the filing of patent family applications and national/regional phase entries in jurisdictions such as Europe, the US, or China, the patent’s protections can be extended beyond Denmark.
4. What are the main risks related to DK2635299’s patent protection?
Potential risks include invalidation due to prior art challenges, claim scope limitations if competitors develop similar compounds outside the patent’s coverage, and overlapping patents that could pose infringement issues.
5. Should competitors consider designing around the claims of DK2635299?
Yes, carefully analyzing the scope of the claims can identify feasible design-around strategies, such as modifying the chemical structure or formulation parameters to avoid infringement.
References
- Danish Patent Office. Patent DK2635299 B1, available from the official register.
- European Patent Office. Patent search reports and prior art references related to pharmaceutical compounds.
- WIPO Patentscope. Family members and international filings associated with DK2635299.
(Note: The above references are illustratively cited, assuming further research would be needed to confirm specific legal documents and patent family data.)
